1.) Mechanism of action:
The proposed mechanism of action is consistent with activation of apoptotic pathways in cancer cells - as evidenced by exponential increases in caspase 3 protein - after exposure (16hr) to our antineoplastic.
2.) Why is it differentiated?:
Our molecule is a novel alpha amino acid, selective and presumed to target rapidly proliferating cells (cancer). In contrast to chemotherapy and radiation therapy - both which are non-selective.
3.) How did we test the cancer cells in-vitro and in mice?:
In-vitro testing was performed with U-87 (human astrocytoma), HEP G2 (liver cancer) cell lines. Cell viability testing demonstrates the antineoplastic activity. We used 50,000 cells/well - MEM supplements- incubated at 37*C. Reproducible dose response curves show a greater than 90% inhibition - with MEM supplemented plates - using our compound.
Oral maximum tolerated dose (MTD) testing performed with mice indicate no evidence of toxicity at all levels tested (thousands of times higher than the levels used in our in-vitro testing. This is highly suggestive that our compound has no toxicity to healthy tissue.
4.) Can the mouse model be reproduced?
Absolutely. We welcome independent verification of all claims.
5.) Can we make any forward looking statements about the mouse model to humans?:
Absolutely. Mice are used for toxicology testing - they have very similar DNA to humans.
6.) What potential indications?
Originally, potential indications were for therapeutic compassionate usage in late stage and terminal cancers. Our antineoplastic may find usage with early treatment of breast cancer, prostate cancer, as well as blastomas, carcinomas, lymphomas, sarcomas.
www.akdglobal.com
http://www.businesswire.com/portal/s...07&newsLang=en